BioVie Highlights Pipeline Progress Ahead of Investor Webinar
Event summary
- BioVie to host investor webinar on March 4, 2026, featuring CEO Cuong Do.
- Focus on bezisterim (NE3107) for Alzheimer’s, Parkinson’s, and Long COVID.
- BIV201 orphan drug candidate advancing toward Phase 3 trial for cirrhosis and ascites.
- Company highlights multi-billion-dollar market opportunities in neurological and liver diseases.
The big picture
BioVie’s webinar underscores its dual focus on neurological and liver disease therapies, aligning with growing demand for treatments targeting inflammation and insulin resistance. The company’s progress in orphan drug development and late-stage clinical programs positions it within a competitive biopharmaceutical landscape, where successful execution could drive significant value creation.
What we're watching
- Clinical Milestones
- Whether bezisterim can sustain encouraging signals in late-stage trials.
- Regulatory Pathway
- The pace at which BIV201 advances through Phase 3 for cirrhosis and ascites.
- Partnership Potential
- How BioVie leverages multi-billion-dollar market opportunities to secure strategic alliances.
Our editorial coverage: